Business & Economy · 1 views
Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff
Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events.
Business & Economy 
Story intelligence
Coverage Single outlet Single-outlet story
Views 1 Community interest
Brief read Under 1 min brief 35 words
AI Summary
Novartis’s recent trial of a cholesterol‑lowering drug targeting Lp(a) failed, prompting a selloff across biopharma stocks. The company had invested in the approach, hoping that reducing Lp(a) would lower the risk of fatal cardiovascular events.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Business & Economy
Continue reading recent Business & Economy coverage
- Dow drops 600 points to start shortened week as oil prices climb: Live updatesContinue reading
- The traditional paths to building wealth are becoming less accessible for young AmericansContinue reading
- Google DeepMind publishes AI-powered predictions for the effect of all 9 billion possible single-point mutations in the human genomeContinue reading
- ‘Poverty doesn’t have to be my reality’: I thought I’d have to rely on Social Security. Then I taught myself how to invest.Continue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow